MedTrace Logo

Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs

NCT02630654 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 404

Last updated 2021-12-07

No results posted yet for this study

Summary

This exploratory study aims to evaluate the diagnostic, prognostic and response predictive value of a multi biomarker strategy in patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs) originating from the midgut or pancreas. Using a recently developed methodology enabling the evaluation of 92 concomitant cancer biomarkers will provide an interesting approach to solve this question (Lundberg et al 2011).

Conditions

  • Gastroenteropancreatic Neuroendocrine Tumors

Interventions

OTHER

This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician.

Sponsors & Collaborators

Principal Investigators

  • Ipsen Medical Director · Ipsen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-03-24
Primary Completion
2021-11-09
Completion
2021-11-09

Countries

  • Denmark
  • Estonia
  • Finland
  • Latvia
  • Lithuania
  • Norway
  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02630654 on ClinicalTrials.gov